日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Discordance in amyloid positivity between visual reads and Centiloids: Impact of white matter uptake

视觉判读与Centiloid检测结果中淀粉样蛋白阳性率的差异:白质摄取的影响

Charil, Arnaud; Nelson, Todd M; Reilhac, Anthonin; Devanarayan, Viswanath; Dhadda, Shobha; Irizarry, Michael C; Kramer, Lynn D; Reyderman, Larisa

Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes

Lecanemab 用于治疗早期阿尔茨海默病 (AD) 患者,这些患者为载脂蛋白 E ε4 (ApoE ε4) 非携带者或杂合子。

Perry, Richard; Kipps, Christopher; Soto Martín, Maria Eugenia; Bozzali, Marco; Logroscino, Giancarlo; Trafford, Sarah; Dhadda, Shobha; Kanekiyo, Michio; Goodwin, Amanda; Hodgkinson, Mark; Hersch, Steven; Irizarry, Michael; Kramer, Lynn; Froelich, Lutz

Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507]

对“Lecanemab 用于治疗载脂蛋白 E ε4 (ApoE ε4) 非携带者或杂合子早期阿尔茨海默病 (AD) 患者的更正”[阿尔茨海默病预防杂志 (2026) 100507]

Perry, Richard; Kipps, Christopher; Martín, Maria Eugenia Soto; Bozzali, Marco; Logroscino, Giancarlo; Trafford, Sarah; Dhadda, Shobha; Kanekiyo, Michio; Goodwin, Amanda; Hodgkinson, Mark; Hersch, Steven; Irizarry, Michael; Kramer, Lynn; Froelich, Lutz

Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open-label extension study

lecanemab治疗早期阿尔茨海默病的长期安全性和有效性:来自clarity AD开放标签扩展研究的结果

van Dyck, Christopher H; Sperling, Reisa; Johnson, Keith; Dhadda, Shobha; Kanekiyo, Michio; Li, David; Gee, Michelle; Hersch, Steven; Irizarry, Michael; Kramer, Lynn

GDF15 protein as a complementary pathology biomarker of Alzheimer's Disease

GDF15蛋白作为阿尔茨海默病的一种辅助病理学生物标志物

Zeng, Xuemei; Deek, Rebecca A; Nafash, Michel N; Gu, Jeremy M; Choity, Lamia; Lafferty, Tara K; Farinas, Marissa F; Bedison, Margaret A; Mercurio, Rocco B; Matan, Cristy; Gogola, Alexandra; Kofler, Julia K; Tudorascu, Dana L; Shaaban, C Elizabeth; Lingler, Jennifer H; Pascoal, Tharick A; Klunk, William E; Villemagne, Victor L; Ikonomovic, Milos D; Berman, Sarah B; Sweet, Robert; Snitz, Beth E; Cohen, Ann D; Kamboh, M Ilyas; Lopez, Oscar L; Karikari, Thomas K; Cui, Mei; Jin, Zishuo; Wang, Yingzhe; Dong, Qiang; Kumari, Namrata; Sodders, Maggie; Marathi, Archana; Olsen, Abby; Potvin‐Trottier, Laurent; Guay‐Lord, Robin; Breuillaud, Lionel; Zehntner, Simone P; Brison, Elodie; Bedell, Barry J; Eslick, Shaun; Austin, Grace; Ferguson, Jessica; Oldmeadow, Christopher; Garg, Manohar; Martins, Ralph N; Jacobs, Tovia; Cejudo, Jaime Ramos; He, Mark; Muller, Matthew; Figueredo, Luisa F; Berger, Jeffrey S; Osorio, Ricardo S; Reyderman, Larisa; Penner, Natasha; Bhagunde, Pratik; Li, David; Dhadda, Shobha; Hersch, Steven; Irizarry, Michael C; Kramer, Lynn D; Koerich, Suelyn; Ramirez, Santiago; Astudillo, Natalia; Colpo, Gabriela Delevati; Soto, Claudio; Salvadori, Sofia Gallo; Baldasso, Gabriela Mantovani; Limberger, Christian; Zimmer, Eduardo R; Das, Glori; Raghunathan, Raksha; Wang, Lin; Wan, Zhihao; Zhao, Hong; Wong, Stephen TC; Kang, Heekyoung; Yoo, Heejin; Shin, Daeun; Seo, Sang Won; Manly, Jennifer J; Brickman, Adam; Kim, Soobin; Culbertson, Michael; Grodsky, Eric; Muller, Chandra; Warren, John Robert; Kanyinda, Jonathan Nyandu; Marola, Olivia J; Howell, Gareth R; Paes, Rodrigo Sebben; Baldasso, Gabriela Mantovani; Limberger, Christian; Zimmer, Eduardo R

Combining CSF MTBR-tau243 and plasma pTau217 ratio enhances the prediction of continuous regional tau PET burden in early Alzheimer's disease

脑脊液 MTBR-tau243 与血浆 pTau217 比值相结合,可提高对早期阿尔茨海默病中连续区域 tau PET 负荷的预测能力。

Devanarayan, Viswanath; Horie, Kanta; Wildsmith, Kristin; Doherty, Thomas; Andreozzi, Erica; Charil, Arnaud; Sachdev, Pallavi; Kramer, Lynn D; Dhadda, Shobha; Irizarry, Michael C

Predicted natural progression as an Alzheimer's prognostic covariate improves the precision of lecanemab efficacy assessments and clinical trial efficiency

将预测的自然进展作为阿尔茨海默病预后协变量,可提高lecanemab疗效评估的精确度和临床试验效率。

Devanarayan, Viswanath; Ye, Yuanqing; Zhu, Liang; Tian, Lu; Kramer, Lynn; Irizarry, Michael; Dhadda, Shobha

Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease

利用多模态预后模型分析个体认知轨迹,以提高阿尔茨海默病临床前试验的效率

Devanarayan, Viswanath; Donohue, Michael C; Sperling, Reisa A; Johnson, Keith A; Ye, Yuanqing; Charil, Arnaud; Doherty, Thomas; Tian, Lu; Raman, Rema; Aisen, Paul S; Kramer, Lynn D; Irizarry, Michael C; Dhadda, Shobha

Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid-positive early Alzheimer's disease

血浆 pTau217 比值可预测淀粉样蛋白阳性早期阿尔茨海默病中脑内 tau 蛋白的持续区域性积累

Devanarayan, Viswanath; Charil, Arnaud; Horie, Kanta; Doherty, Thomas; Llano, Daniel A; Andreozzi, Erica; Sachdev, Pallavi; Ye, Yuanqing; Murali, Leema Krishna; Zhou, Jin; Reyderman, Larisa; Hampel, Harald; Kramer, Lynn D; Dhadda, Shobha; Irizarry, Michael C

Response to Xing et al.: post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database

对邢等人的回应:关于Lecanemab上市后安全性问题的探讨:一项基于FDA不良事件报告系统数据库的药物警戒研究

Irizarry, Michael; Surick, Ilona; Michael, Ari; D Kramer, Lynn